Perrigo cuts FY25 adjusted EPS view to $2.70-$2.80 from $2.90-$3.10

Consensus $2.98. Cuts FY25 revenue view to down 2.5%-3% from flat to up 3%. “As we look ahead, we’re adjusting our full-year 2025 outlook to reflect infant formula industry dynamics and soft OTC consumption trends. We are, however, managing through these with discipline by leveraging share gains and accretive initiatives to support expected mid-to-high single-digit adjusted EPS growth for the year. To drive a more consistent and focused growth profile, we continue to evaluate and action our portfolio, including the previously announced agreement to divest our Dermacosmetics business, the previously disclosed strategic review of our Oral Care business, and today’s announcement to proactively conduct a strategic review of our Infant Formula business. In a tough environment, Perrigo (PRGO) is winning with consumers and customers,” concluded Lockwood-Taylor.